Ashvattha Therapeutics

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing a new class of precision nanomedicines built on hydroxyl dendrimer therapeutics (HDTs), a platform exclusively licensed from Johns Hopkins University. Hydroxyl dendrimers traverse tissue barriers such as the blood-retinal and blood-brain barrier and are selectively taken up by activated cells in regions of inflammation, allowing known small-molecule drugs to be delivered intracellularly to diseased tissue with sustained effect and reduced off-target exposure. The company is advancing programs across ophthalmology, neurology, and inflammatory disease, led by migaldendranib (MGB), a first-in-class subcutaneously administered nanomedicine in Phase 2 development for diabetic macular edema and neovascular age-related macular degeneration, plus hydroxyl dendrimer PET imaging tracers such as [18F]OP-801. Founded by Jeffrey L. Cleland, Kannan Rangaramanujam, and Sujatha Kannan. Ashvattha publishes no public developer program, API, or machine-readable interface.

Ashvattha Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Nanomedicine.

Ashvattha Therapeutics’ developer surface includes engineering blog and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

9.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesNanomedicineDrug DevelopmentClinical TrialsOphthalmologyNeurologyHealth

Kin Score

Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1

Composite quality — 9.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.9 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ashvattha-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

About

Blog

BlogRSS

Careers

LinkedIn

Other 4

Properties that don't map to a standard resource type

Technology

Pipeline

Resources

SecondaryMarket

Source (apis.yml)

aid: ashvattha-therapeutics
name: Ashvattha Therapeutics
description: Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing a new class of precision nanomedicines
  built on hydroxyl dendrimer therapeutics (HDTs), a platform exclusively licensed from Johns Hopkins University. Hydroxyl
  dendrimers traverse tissue barriers such as the blood-retinal and blood-brain barrier and are selectively taken up by activated
  cells in regions of inflammation, allowing known small-molecule drugs to be delivered intracellularly to diseased tissue
  with sustained effect and reduced off-target exposure. The company is advancing programs across ophthalmology, neurology,
  and inflammatory disease, led by migaldendranib (MGB), a first-in-class subcutaneously administered nanomedicine in Phase
  2 development for diabetic macular edema and neovascular age-related macular degeneration, plus hydroxyl dendrimer PET imaging
  tracers such as [18F]OP-801. Founded by Jeffrey L. Cleland, Kannan Rangaramanujam, and Sujatha Kannan. Ashvattha publishes
  no public developer program, API, or machine-readable interface.
url: https://raw.githubusercontent.com/api-evangelist/ashvattha-therapeutics/refs/heads/main/apis.yml
image: https://avttx.com/wp-content/uploads/2019/05/logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-07-31'
modified: '2026-07-31'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Nanomedicine
- Drug Development
- Clinical Trials
- Ophthalmology
- Neurology
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-31'
  status: minimal
  artifacts_added: 3
  pass: local-v1
common:
- type: DomainSecurity
  url: security/ashvattha-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/ashvattha-therapeutics-llms.txt
- type: Website
  url: https://avttx.com/
- type: About
  url: https://avttx.com/about/
- type: Technology
  url: https://avttx.com/technology/
- type: Pipeline
  url: https://avttx.com/pipeline/
- type: Blog
  name: News
  url: https://avttx.com/news/
- type: BlogRSS
  name: News RSS
  url: https://avttx.com/feed/
- type: Resources
  url: https://avttx.com/resources/
- type: Careers
  url: https://avttx.com/careers/
- type: Contact
  url: https://avttx.com/contact/
- type: PrivacyPolicy
  url: https://avttx.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/ashvattha-therapeutics-inc
- type: SecondaryMarket
  name: Forge Global listing
  url: https://forgeglobal.com/ashvattha-therapeutics_stock/